Surgery is the gold standard, GLP-1s are all the rage—whether a head-to-head study is needed depends on who you ask.

This cross-sectional study showed websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially ...

Six out of 31 total new small molecules approved by the FDA in 2024 were produced by Wuxi, said the company's co-CEO.

Despite constraints exerted by GLP-1RAs on bariatric surgery volumes, shares in Intuitive Surgical surged following a ...

Industry experts discuss the current landscape, explore today’s support options, and find out which trends will dominate heart-health space in 2025.

Patients with obesity and comorbid cardiovascular disease were more likely to ration prescription drugs than those without obesity.

The following is a summary of “Effects of Novel Antidiabetic Agents on Contrast-Associated Acute Kidney Injury in Diabetic Patients Undergoing Percutaneous Coronary Intervention,” published in the ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

Hanmi Pharmaceutical develops obesity drugs to increase muscle while reducing fat Hanmi Pharmaceutical pioneers innovative ...